Long-Term Pain, Stiffness, and Functional Disability After Total Knee Arthroplasty With and Without an Extended Ambulatory Continuous Femoral Nerve Block

A Prospective, 1-Year Follow-Up of a Multicenter, Randomized, Triple-Masked, Placebo-Controlled Trial

Brian M. Ilfeld, MD, MS,* Jonathan J. Shuster, PhD,† Douglas W. Theriaque, MS,‡ Edward R. Mariano, MD, MAS,§ Paul J. Girard, MD,** Vanessa J. Loland, MD,¶ R. Scott Meyer, MD,## John F. Donovan, MD,ǁ George A. Pugh, MD,†† Linda T. Le, MD,‡‡ Daniel I. Sessler, MD,§§ and Scott T. Ball, MD||||

From the *Department of Anesthesiology, University of California San Diego, San Diego, CA; †Department of Health Outcomes and Policy, ‡Clinical and Translational Science Institute, University of Florida, Gainesville, FL; Department of Anesthesiology, University of California, San Francisco; ¶Department of Orthopaedic Surgery, Veteran’s Affairs Medical Center, La Jolla; **Department of Anesthesiology, University of California, San Diego; ††Department of Orthopaedic Surgery, the Alta Bates Summit Medical Center, Oakland, CA; ‡‡Department of Anesthesiology, University of California, San Francisco; §§Department of Orthopaedic Surgery, University of California, San Diego, CA; ||||Department of Orthopaedics, University of California, San Diego, CA. Accepted for publication October 27, 2010. Address correspondence to: Brian M. Ilfeld, MD, MS, 200 West Arbor Dr, MC 8770, San Diego, CA 92103-8770 (e-mail: bilfeld@ucsd.edu).

Background: Previously, we have demonstrated that extending a continuous femoral nerve block (cFNB) from overnight to 4 days after total knee arthroplasty (TKA) provides clear benefits during the infusion, but not subsequent to catheter removal. However, there were major limitations in generalizing the results of that investigation, and we subsequently performed a very similar study using a multicenter format, with many health care providers, in patients on general orthopedic wards, thus greatly improving inference of the results to the general population. Not surprisingly, the perioperative/short-term outcomes differed greatly from the first, more limited study. We now present a prospective follow-up study of the previously published, multicenter, randomized controlled clinical trial to investigate the possibility that an extended ambulatory cFNB decreases long-term pain, stiffness, and functional disability after TKA, which greatly improves inference of the results to the general population.

Methods: Subjects undergoing TKA received a cFNB with ropivacaine 0.2% from surgery until the following morning, at which time patients were randomized to continue either perineural ropivacaine (n = 28) or normal saline (n = 26). Patients were discharged with their catheter and a portable infusion pump, and catheters were removed on postoperative day 4. Health-related quality of life was measured using the Western Ontario and McMaster Universities Osteoarthritis Index preoperatively and then at 7 days, as well as 1, 2, 3, 6, and 12 months after surgery. This index evaluates pain, stiffness, and physical functional disability. For inclusion in the analysis, we required a minimum of 4 of the 6 time points, including day 7 and at least 2 of months 3, 6, and 12.

Results: The 2 treatment groups had similar Western Ontario and McMaster Universities Osteoarthritis scores for the mean area-under-the-curve calculations (point estimate for the difference in mean area under the curve for the 2 groups [overnight infusion group − extended infusion group] = 3.8; 95% confidence interval, −3.8 to +11.3; P = 0.32) and at all individual time points (P > 0.05).

Conclusions: This investigation found no evidence that extending an overnight cFNB to 4 days improves (or worsens) subsequent pain, stiffness, or physical function after TKA in patients of multiple centers convalescing on general orthopedic wards.

(T Reg Anesth Pain Med 2011;36: 116–120)

Total knee arthroplasty (TKA) often results not only in severe perioperative pain and debilitation, but also chronic pain, joint stiffness, and functional disability for many months or even years after the procedure. Persistent postoperative pain is strongly associated with preoperative pain, poorly controlled postoperative pain, and the type of surgery. Providing potent perioperative analgesia accelerates passive knee flexion in the first 2 months after TKA, but whether persistent pain and functional disability are decreased remains undetermined.

We previously reported, for example, that extending a continuous femoral nerve block (cFNB) from overnight to 4 days after TKA improves analgesia during the infusion. However, a study of health-related quality of life during the first year for subjects of our original study failed to detect any long-term benefits from extending the cFNB to 4 days. Unfortunately, there were limitations in generalizing the results of that investigation, and we therefore subsequently performed a very similar study in a multicenter format, with many health care providers, in patients on general orthopedic wards.
We now present a prospective follow-up study of the previously published, multicenter, randomized controlled clinical trial to investigate the possibility that an extended ambulatory cFNB decreases long-term pain, stiffness, and functional disability after TKA, which greatly improves inference of the results to the general population. We hypothesized that an improvement in pain, stiffness, and functional ability would be greater not only at 1 week, but also at 1, 2, 3, 6, and 12 months after TKA in patients who received a 4-day cFNB compared with an overnight cFNB in the immediate postoperative period.

MATERIALS AND METHODS

The institutional review board at each participating clinical center approved all study procedures, and the trial was prospectively registered at clinicaltrials.gov (NCT00419276). All subjects provided written, informed consent, and because this was a multicenter trial, a Data Safety Monitoring Board (University of California San Diego, San Diego, Calif) reviewed data and adverse events every 6 months. Details of the study methods have been published previously.

In brief, patients offered enrollment included adults (18–75 years old) with osteoarthritis scheduled for primary, unilateral, tricompartment, cemented TKA via a 12- to 18-cm midline skin incision and parapatellar approach who desired a cFNB for postoperative analgesia.

Study Intervention

Subjects received a femoral nerve block and perineural catheter (Stimucath; Arrow International, Reading, Pa) followed by a perineural ropivacaine 0.2% infusion (6 mL/hr basal; 4-mL patient-controlled bolus; 30-min lockout) from surgery until the following morning, at which time patients were randomized to either continue perineural ropivacaine ("extended infusion," n = 39) or switched to normal saline ("overnight infusion," n = 38). Randomization was performed in a triple-masked fashion (patients, investigators, statisticians) with stratification according to clinical site.

At 1800 on postoperative day (POD) 2 (36 hrs after randomization), a portable infusion pump (Pain Pump 2 Blockaid; Stryker Instruments, Kalamazoo, Mich) containing 400 mL of the same study solution (basal 5 mL/hr; bolus 4 mL; 60-min lockout) replaced the previous infusion pump. Patients were discharged with their pump and perineural catheter in situ as early as 1000 on POD 3. In the evening of POD 4, patients' caretakers removed the femoral catheters with physician instructions provided by telephone.

Outcome Measurements

The current study was a planned secondary analysis of prospectively collected data involving pain, joint stiffness, and physical functional disability. Various instruments are available that convert health status into quantifiable values. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is an instrument specifically designed to evaluate clinically important, patient-relevant changes in health-related quality of life after treatment interventions in patients with osteoarthritis of the knee. The WOMAC evaluates 3 dimensions of health-related quality of life: pain, stiffness, and physical functional disability with 5, 2, and 17 questions, respectively. An ordinal Likert scale from 0 to 4 is used for each question, with lower scores indicating lower levels of symptoms or physical disability.

Each subscale is summed to a maximum score of 20, 8, and 68, respectively. The individual dimensions are always analyzed separately, and investigators have often added a "global" score, which is calculated by summing the scores for the 3 subscales. The questionnaire may be self-administered or administered via a telephone call and takes 5 to 10 mins to complete. Because it is a proprietary instrument, the questionnaire itself may not be published and is therefore not included in an appendix.

Since its inception 2 decades ago, the WOMAC has been translated into 60 languages and used in several hundred published clinical trials. It has been rigorously examined, demonstrating excellent construct validity, responsiveness, and test-retest reliability in patients after total knee replacement and is therefore recommended in the Osteoarthritis International Research Society's guidelines for clinical trials.

Therefore, to investigate the relationship between postoperative analgesic technique and subsequent pain, stiffness, and functional disability, a baseline WOMAC was administered before surgery (POD 0) and again at 7 days as well as 1, 2, 3, 6, and 12 months after surgery. The baseline measurement was a self-administered written questionnaire, whereas subsequent measurements were administered via the telephone. Scores from self-administered and telephone-administered WOMAC instruments have a demonstrated error rate of 0.9% to 2.6%.

Statistical Analysis

The study was powered for the previously published primary end point: time to attain 3 discharge criteria (adequate analgesia, independence from intravenous analgesics, and ambulation of at least 30 m). To analyze the WOMAC responses, the WOMAC scores were joined by straight lines between time points (t) from POD 7 (t = 0.25 months) to t = 12 months. The personal progress estimated mean area under the curve (AUC) was defined as the integral of this curve from 0.25 to 12, divided by 11.75 months. The WOMAC hypotheses asked the question of whether overall personal means over a continuum for 12 months of the WOMAC scores (mean area under the curve) differ between treatment groups.

The mean AUC measurements were compared by a 2-sided t test with a pooled variance estimate, as the primary question of the null hypothesis was that the 2 groups have the same WOMAC profile over time. For inclusion in this specific analysis, we required a minimum of 4 of the 6 time points, including day 7 and at least 2 of months 3, 6, and 12. For missing time points, we applied a slightly modified trapezoidal rule, commonly used in pharmacokinetic studies, which effectively imputes missing values by linear interpolation between the values on either side of the one missing or, in the case of month 12, linear extrapolation from the values of months 3 and 6. The only modification occurred if the extrapolated value falls below zero, in which case a value of zero was used as month 12. These rules were set up before the study was conducted. Additional secondary analyses involved time point by time-point comparison of the changes from baseline in AUC for total scores, plus the same for pain, stiffness, and functional subscales.

RESULTS

Subjects were enrolled during a 29-month period between April 2007 and August 2009. Details of the study results for the immediate postoperative period have been published previously. Data acquisition for the current study involving WOMAC scores occurred 7 days to 12 months after enrollment of each subject. No patient was lost to follow-up. However, for the mean AUC calculations, follow-up WOMAC data meeting our stringent inclusion criteria (a minimum of 4 of the 6 time points, including day 7 and at least 2 of months 3, 6, and 12) were available from 28 subjects (72%) from the extended infusion and 26 subjects (68%) from the overnight infusion groups. The 2 treatment groups had similar WOMAC scores for the mean AUC calculations (point estimate for the difference in...
mean area under the curve for the 2 groups [overnight infusion group − extended infusion group] = 3.8; 95% confidence interval, −3.8 to +11.3; \( P = 0.32\)). In addition, the 2 treatment groups had similar total WOMAC scores at all individual time points in terms of both raw scores and changes from the baseline \( (P > 0.05; \text{Figs. 1 and 2, and Table 1})\). Although there appeared to be a trend toward improved WOMAC scores in the extended infusion group at month 2 \( (P = 0.09)\), this difference disappeared after adjusting for baseline values \( (P = 0.62)\).

A retrospective power calculation indicates that a study of 54 subjects (26 in one group and 28 in the other) has 80% power at \( P = 0.05 \) (2-sided) to detect a difference of 0.78 SDs in mean AUC. This would translate to a sensitivity of about a 10-unit difference between the groups.

**DISCUSSION**

This prospective, multicenter investigation found no evidence that extending an overnight cFNB to 4 days decreases subsequent postinfusion pain, stiffness, or functional disability between 7 days and 12 months after TKA. In contrast, multiple randomized controlled trials have demonstrated clear benefits during the infusion.\(^3,4,6,15,16\)

**Preemptive Analgesia**

There are both theoretical reasons and clinical data suggesting that improving analgesia in the immediate postoperative period may decrease long-term pain, reduce joint stiffness, and improve functional status.\(^17–21\) For example, there are analogous data involving continuous epidural infusion effects on post-thoracotomy pain in which patients randomized to receive a thoracic bupivacaine/morphine epidural infusion from before surgery through 48 postoperative hrs reported superior analgesia during the infusion when compared with patients randomized to receive intravenous patient-controlled morphine\(^21\) (similar to cFNB and TKA as reported in other studies\(^3,15\)). After the epidural catheter was removed, patients who had received 2 days of epidural infusion had a lower risk of thoracotomy-associated pain at 2 (50% vs 87%, \( P < 0.05 \)) and 6 months (45% vs 78%, \( P < 0.05 \)) after surgery, as compared with patients receiving only intravenous opioids. Thus, the lack of long-term effect for an extended-duration cFNB of the current study is disappointing. Although there may be short-term analgesic benefits after cFNB discontinuation—2 randomized controlled studies removed...
catheters on POD 2 and still found a small improvement in pain scores 24 to 48 hrs later\textsuperscript{16,22}—there are currently few data to suggest that persistent chronic pain after catheter removal may be reduced with cFNB after TKA.

**Study Limitations**

A limitation of our study is that the control group received an initial femoral nerve block followed by an overnight cFNB and not simply a single-injection femoral nerve block and/or opioids as is common in many practices in the United States. For TKA patients who do not receive any single-injection and/or continuous peripheral nerve block(s), the differences in postoperative health-related quality of life compared with a 4-day cFNB as provided in this study may be much greater in the months after surgery. More importantly, WOMAC scores were secondary outcomes for the original study and thus do not have the statistical strength of primary outcomes. Nonetheless, our results do not suggest that there was any large effect of extending the cFNB from overnight to 4 PODs. In addition, the individual means, variances, and covariances at and between specific time points provided by this study may be used as planning parameters for future investigations. Lastly, the intervention protocol used in this investigation reflected our clinical practice during the study period. However, few data are available to define the optimal post-TKA infusion protocol. It is possible that an alternative infusion protocol would result in different findings than our study.

It is noteworthy that, as previously reported, there were a total of 4 falls during the cFNB in subjects receiving perineural ropivacaine, compared with none receiving perineural saline (\(P = 0.24\)).\textsuperscript{6} Since that initial publication, a causal relationship has been demonstrated between continuous peripheral nerve blocks involving the femoral nerve and the risk of falling after knee and hip arthroplasty.\textsuperscript{23} Combined with the negative WOMAC results of the current and previous studies,\textsuperscript{7} the optimal duration of cFNB after knee arthroplasty must be questioned—the benefits of an extended-duration infusion must be balanced against the potential risks.

**ACKNOWLEDGMENTS**

The authors thank Thomas Peatman, MD, attending physician, Department of Orthopedics, Alta Bates Summit Medical Center (Oakland, Calif); Beverly Morris, MBA, RN, CNP, educator, Department of Nursing, University of California, San Diego; Eliza Ferguson, BS, and Rosalita Maldonado, BS, both research coordinators, Department of Anesthesiology, University of California, San Diego; and Vickie Nolan, RN, CCRC, clinical research manager, Jordan Research and Education Institute, Alta Bates Summit Medical Center; for their invaluable assistance.

**REFERENCES**


